Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05116826 · ClinicalTrials.gov registry record · Phase 1
Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients
A Phase 1 study of Liver Diseases and Moderate Hepatic Impairment, sponsored by Genfit.
- Completed
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 2
- Study locations
NCT05116826 is a Phase 1 study of Liver Diseases and Moderate Hepatic Impairment that has completed, run by Genfit. The registered enrollment target is 25 participants, below the 61,158-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The trial reports 2 study locations across 1 state.
The verdict
NCT05116826, a Phase 1 study of Liver Diseases and Moderate Hepatic Impairment, has completed, sponsored by Genfit.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 2
- Study locations
Study Summary
This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
Conditions Studied
Interventions
- DRUG Nitazoxanide
Study Locations (2)
Florida
- Panax Clinical Research - Miami Lakes
- Orlando Clinical Research Center - Orlando
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2021-11-05 |
| Est. Completion | 2022-04-13 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05116826
The ClinicalTrials.gov registry entry for NCT05116826 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 61,158-participant average among 33 other Liver Diseases trials with a reported enrollment target (100% lower). The listed sponsor is Genfit, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Liver Diseases appearing as the primary indexed condition, and to 1 intervention - of which Nitazoxanide is the first listed.
NCT05116826 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT05116826 about?
NCT05116826 is a clinical study titled "Nitazoxanide Pharmacokinetic Parameters in Hepatic Impaired Patients". This study is being conducted to evaluate the major Nitazoxanide (NTZ) active metabolite in adult participants with hepatic impairment and healthy adults.
What is the current status of trial NCT05116826?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2021-11-05. Estimated completion is 2022-04-13.
What conditions does trial NCT05116826 study?
This clinical trial studies the following conditions: Liver Diseases, Moderate Hepatic Impairment, Severe Hepatic Impairment.
What interventions are being tested in trial NCT05116826?
The interventions under investigation include: Nitazoxanide (DRUG).
Who is sponsoring clinical trial NCT05116826?
This trial is sponsored by Genfit, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05116826 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Liver Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial
RECRUITING · Phase 1
-
A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems
COMPLETED · Phase 1
-
A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild or Moderate Hepatic Impairment on the Multiple-Dose Pharmacokinetics of Ozanimod
COMPLETED · Phase 1
-
Veteran-Centered Care for Advanced Liver Disease (Vet-CALD)
RECRUITING · NA
-
Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
RECRUITING · NA
-
MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.